AelisFarma

CB1-SSi:
A unique pharmacological class stemming from a breakthrough scientific discovery

AelisFarma

Aelis Farma mission:
Develop the therapeutic potential of CB1-SSi

 

CB1 Signaling Specific inhibitors (CB1-SSi) are a proprietary new pharmacological class never tested in humans before that open a new frontier in pharmacology.

 

CB1-SSi have a unique mechanism of action

CB1-SSi are new molecular entities (NME) that mimick a natural defense mechanism of the brain (Science 2014).
CB1-SSi do not block, like available antagonists, all the cellular activities of a receptor.
CB1-SSi correct selectively the cellular activity hyperactivated in the pathological state.
CB1-SSi do not modify normal physiology or behavior and have no identifiable toxicity and side effects.

 

CB1-SSi have broad therapeutic targets:

CB1-SSi modify the principal target of cannabinoid therapeutics, the CB1 receptor, which is involved in a large spectrum of diseases of the central nervous system and peripheral organs.

 

Aelis Farma main disease targets:

Cannabis related disorders (AEF0117)

Cannabis addiction and cannabis-induced psychosis are two major emerging medical needs. There are 12 million of cannabis addicts worldwide and cannabis is the major single cause of acute psychosis. These pathological effects are mediated by the hyperactivation of the CB1 receptor by THC the active principle of cannabis.

Cognitive Deficits (AEF0217)

Cognitive disabilities are one of the major burdens of modern society. AEF0217 is being specifically developed to treat the cognitive deficits in Down syndrome (trisomy 21) and of the elderly.

 

 

 

CB1-SSi:
A unique pharmacological class stemming from a breakthrough scientific discovery

AelisFarma